Synthetic peptide conjugated to KLH derived from within residues 150 - 250 of Human GDNF Receptor alpha 1.
(Peptide available as ab93754.)
Our Abpromise guarantee covers the use of ab84106 in the following tested applications.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 51 kDa (predicted molecular weight: 51 kDa).|
|IP||Use a concentration of 5 µg/ml.|
|ICC/IF||Use a concentration of 5 µg/ml.|
|IHC-P||Use a concentration of 5 µg/ml.|
GDNF Receptor alpha 1 was immunoprecipitated using 0.5mg Mouse Brain tissue, 5µg of Rabbit polyclonal to GDNF Receptor alpha 1 and 50µl of protein G magnetic beads (+). No antibody was added to the control (-).
The antibody was incubated under agitation with Protein G beads for 10min, Mouse Brain tissue lysate diluted in RIPA buffer was added to each sample and incubated for a further 10min under agitation.
Proteins were eluted by addition of 40µl SDS loading buffer and incubated for 10min at 70°C; 10µl of each sample was separated on a SDS PAGE gel, transferred to a nitrocellulose membrane, blocked with 5% BSA and probed with ab84106.
Secondary: Mouse monoclonal [SB62a] Secondary Antibody to Rabbit IgG light chain (HRP) (ab99697).
Band: 51kDa; GDNF Receptor alpha 1, non specific - as present in control (lane 2); We are confident this was due to slight lane contamination and the band seen in the IP lane is our target of interest.
IHC image of GDNF Receptor alpha 1 staining in Human kidney cancer formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab84106, 5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.